Navigation Links
Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
Date:2/22/2012

AMARILLO, Texas, Feb. 22, 2012 /PRNewswire/ -- Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that Dr. Stephen T. Chen has been appointed as Chairman of the Board and Chief Executive Officer.  Dr. Joseph Cummins will remain as President and become Chief Operating Officer. Dr. Chen has been a director of the company since February 1996. He received a PhD degree in Industrial and Physical Pharmacy from Purdue University in 1977 with an emphasis on drug delivery systems.

Dr. Chen has over thirty years of international business experience, including an extensive background in pharmaceutical product acquisition and licensing, development of joint venture agreements, execution of business strategy, and leadership of start-up companies in the pharmaceutical, biotechnology and nutraceutical industries. Dr. Chen has held executive positions in R&D and business development at several major pharmaceutical companies, including Burroughs Wellcome (presently GlaxoSmithKline), Miles Pharmaceuticals (presently Bayer), ICI America (presently AstraZeneca), and Ciba-Geigy (presently Novartis).

About Amarillo Biosciences

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 4% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2010. 

Investor Relations: Philippe Niemetz

PAN Consultants, Ltd.

e-mail:p.niemetz@panconsultants.com
Tel: 212-344-6464

Fax: 212-618-1276

 

Joseph M. Cummins

President and COO

e-mail: jcummins@amarbio.com

Tel: 806-376-1741

Fax: 806-376-9301

 


'/>"/>
SOURCE Amarillo Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amarillo Biosciences Issues Corporate Update
2. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
3. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, ... the disease. Surviving Mesothelioma has just posted an article on the new study. ... their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces parvulus, ...
(Date:5/19/2016)... May 19, 2016  AdvancedFlow Systems Inc. (AFS), ... based out of Maple Ridge, British ... to its existing portfolio of contract manufacturing clients ... along with its sister companies Surround Technologies (STI) ... integrated industrial group that specializes in providing contract ...
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
(Date:5/18/2016)... ... May 18, 2016 , ... ... Summer Camp at The University of Toledo. This two-day camp will take place ... to explore the field of pharmaceutical sciences in preparation for a university academic ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):